Table 3.
Univariate analysis on the risk factors of cetuximab-induced hypersensitivity infusion reactions (CI-IRs)
| Characteristics | N | Patients with CI-IRs (N = 117) |
Patients without CI-IRs (N = 1275) | P-value | ||
|---|---|---|---|---|---|---|
| Age (years), mean ± SD | 1392 | 64.0 ± 9.7 | 62.9 ± 10.6 | 0.28 | ||
| Sex | 0.53 | |||||
| Male, N (%) | 1091 | 89 (8.2) | 1002 (91.8) | |||
| Female, N (%) | 301 | 28 (9.3) | 273 (90.7) | |||
| Primary cancer locations | 0.91 | |||||
| Head and Neck, N (%) | 958 | 81 (8.5) | 877 (91.5) | |||
| Colorectal, N (%) | 347 | 30 (8.6) | 317 (91.3) | |||
| Premedications | 0.46 | |||||
| Corticosteroids alone, N (%) | 19 | 0 | 19 (100) | |||
| H1A alone, N (%) | 11 | 0 | 11 (100) | |||
| Corticosteroids + H1A, N (%) | 1361 | 117 (8.6) | 1244 (91.4) | |||
| Types of chemotherapy regimen | 0.78 | |||||
| Monotherapy, N (%) | 49 | 4 (8.2) | 45 (91.8) | |||
| Polychemotherapy, N (%) | 911 | 80 (8.8) | 831 (91.2) | |||
| Concomittant radiotherapy, N (%) | 432 | 33 (7.6) | 399 (92.4) | |||
| Lyme disease risk areasa | 0.016 | |||||
| High-risk areab, N (%) | 266 | 35 (13.2) | 231 (86.8) | |||
| Medium-risk areac, N (%) | 467 | 33 (7.1) | 434 (92.9) | |||
| Low-risk aread, N (%) | 407 | 33 (8.1) | 374 (91.9) | |||
| Very-low-risk areae, N (%) | 252 | 16 (6.4) | 236 (93.6) | |||
CI-IRs, cetuximab induced hypersensitivity infusion reactions; SD, standard deviation; H1A, histamine-1 receptor antagonist
a defined according to estimated mean annual regional incidence rates of Lyme disease from Septfons A, et al. Epidemiology of Lyme borreliosis through two surveillance systems: the national Sentinelles GP network and the national hospital discharge database, France, 2005 to 2016 Eurosurveillance. 2019;24(11). doi:10.2807/1560-7917.ES.2019.24.11.1800134 [41]. : b > 150 / 100 000 inhabitants; c 50–100 / 100 000 inhabitants; d 20–50 / 100 000 inhabitants; e 5–20 / 100 000 inhabitants